International Medical Research Frontier

Objective To explore the clinical effect of azithromycin in the treatment of mycoplasma pneumonia in children. During the period of 2020, a total of 12 cases of children with mycoplasma pneumonia were divided into two groups: the first part and the second part. Methods 2021 cases of children with mycoplasma pneumonia were divided into two groups. Among them, the first part of the subjects were included in the routine group treated with erythromycin, and the second part of the subjects were included in the experimental group treated with azithromycin. The treatment performance was sorted out, and the clinical treatment effect, symptom improvement index, incidence of adverse reactions and inflammatory factor level before and after treatment were compared between the two groups. Results before treatment, there was no difference in the level of inflammatory factors between the two groups (P > 0.05). After treatment, the level of inflammatory factors and the incidence of adverse reactions in the experimental group were lower than those in the conventional group (P < 0.05). Compared with the routine group, the symptom improvement index of the experimental group was better (P < 0.05). Compared with the routine group, the clinical therapeutic effect of the experimental group was higher (P < 0.05). Conclusion Azithromycin can inhibit pathological symptoms and eliminate inflammatory reaction in children with mycoplasma pneumonia. It is suggested to popularize the safety of drug use.

Mycoplasma pneumonia in children; Azithromycin; Erythromycin; Treatment effect